The earnings call highlighted robust growth in MRD revenue, improved gross margins, and strategic advancements in payer contracting, along with a significant reduction in cash burn. However, there was a slight decline in Immune Medicine revenue due to expected reductions in Genentech amortization.

Company Guidance -

Q2 2025

During the earnings call for Adaptive Biotechnologies, the company provided updated guidance reflecting improved financial performance and strategic initiatives. They reported a 34% increase in MRD revenue year-over-year, driven by growth in clinical volumes, ASPs, and pharma sequencing. The company raised its full-year MRD revenue guidance to $180-$190 million, with an expectation of approximately 30% clonoSEQ test volume growth. Sequencing gross margin improved by 17 percentage points to 62%, and operating expenses decreased by 9%, resulting in a cash burn reduction of 38% compared to the previous year. Adaptive's cash position was reported at $233 million, providing confidence in achieving strategic objectives without raising additional capital. The company aims to achieve an average ASP of $1,300 per test for fiscal year 2025, with expectations to be adjusted EBITDA positive in the second half of the year. The management highlighted continued progress in their immune medicine business and upcoming launches and integrations to further drive growth.

Strong MRD Revenue Growth

MRD revenue increased by 34% to $43.7 million, with clinical and pharma contributions of 65% and 35%, respectively. ClonoSEQ clinical revenue grew by 55% versus the prior year.

Sequencing Gross Margin Improvement

Sequencing gross margin improved by 17 percentage points year-over-year to 62%.

Reduction in Operating Expenses

Operating expenses decreased by 9%, highlighting disciplined cost management.

Cash Burn Reduction

Cash burn for the quarter was $23 million, a 38% improvement compared to the same period last year.

Record ClonoSEQ Test Volumes

Tests delivered reached a new record high of over 23,000 in the quarter, representing a 36% increase versus the prior year.

Successful Payer Contracting

Closed six key agreements with major national payers, including Aetna, Humana, and Anthem, aiming for an average ASP of $1,300 per test for fiscal year 2025.

Adaptive Biotechnologies (ADPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2025	2025 (Q2)	-0.24 / -	-0.31	―	―	―
May 01, 2025	2025 (Q1)	-0.29 / -0.20	-0.33	39.39% (+0.13)
Feb 11, 2025	2024 (Q4)	-0.26 / -0.23	-0.48	52.08% (+0.25)
Nov 07, 2024	2024 (Q3)	-0.29 / -0.22	-0.35	37.14% (+0.13)
Aug 01, 2024	2024 (Q2)	-0.33 / -0.31	-0.33	6.06% (+0.02)
May 07, 2024	2024 (Q1)	-0.35 / -0.33	-0.4	17.50% (+0.07)
Feb 14, 2024	2023 (Q4)	-0.33 / -0.48	-0.28	-71.43% (-0.20)
Nov 09, 2023	2023 (Q3)	-0.34 / -0.35	-0.32	-9.37% (-0.03)
Aug 02, 2023	2023 (Q2)	-0.35 / -0.33	-0.37	10.81% (+0.04)
May 03, 2023	2023 (Q1)	-0.38 / -0.40	-0.44	9.09% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ADPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$7.36	$9.84	+33.70%
Feb 11, 2025	$7.80	$7.55	-3.21%
Nov 07, 2024	$5.63	$5.82	+3.37%
Aug 01, 2024	$4.45	$4.30	-3.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Adaptive Biotechnologies Corp (ADPT) report earnings?

Adaptive Biotechnologies Corp (ADPT) is schdueled to report earning on Aug 05, 2025, After Close (Confirmed).

What is Adaptive Biotechnologies Corp (ADPT) earnings time?

Adaptive Biotechnologies Corp (ADPT) earnings time is at Aug 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ADPT EPS forecast?

ADPT EPS forecast for the fiscal quarter 2025 (Q2) is -0.24.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing